# The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/the-benefit-and-risk-of-addition-of-pd-1-pd-l1-inhibitors-to-chemotherapy-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Deping Luo,Ying Yu,Qi Wang,Tao Peng,Chan Li,Wenxiong Zhang,Jing Huang |
| Citations | 9 |
| DOI | 10.1186/s12885-025-13843-4 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-025-13843-4 |
| OpenAlex ID | https://openalex.org/W4408357544 |
| PMID | 40075324 |
| Type | article |
| Year | 2025 |

## Paper authors

- [Ying Yu](https://scholariq.org/researchers/ying-yu/)

## Paper journal

- [BMC Cancer](https://scholariq.org/journals/bmc-cancer/)

## Paper primary topic

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

## Paper topics

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.